Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells

Oncogene

Volumn 35, Issue 39, 2016, Pages 5191-5201

  Lee, I I ^a   Maniar, K ^a   Lydon, J P ^b   Kim, J J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; GESTAGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR B; PROTEIN KINASE B; SMALL INTERFERING RNA; AKT1 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; PROGESTERONE RECEPTOR; PROMEGESTONE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER HORMONE THERAPY; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENDOMETRIAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROGESTINS; PROMEGESTONE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, PROGESTERONE; TRANSCRIPTION, GENETIC;

EID: 84961390334     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.56     Document Type: Article

References (41)

1. National Cancer Institute. SEER Stat Fact Sheets: Endometrial Cancer, vol. 2015, 2015
2. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16: 8-13
3. Erkanli S, Ayhan A. Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer 2010; 20: 1170-1187
4. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: A literature review. Gynecol Oncol 2004; 95: 133-138
5. Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist 2015; 20: 270-278
6. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007; 25: 2798-2803
7. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-1744
8. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 2011; 22: 145-152
9. Dai D, Kumar NS, Wolf DM, Leslie KK. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. Am J Obstet Gynecol 2001; 184: 790-797
10. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 2002; 62: 881-886
11. Smid-Koopman E, Blok LJ, Kuhne LC, Burger CW, Helmerhorst TJ, Brinkmann AO et al. Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Invest 2003; 10: 49-57
12. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73
13. Gu C, Zhang Z, Yu Y, Liu Y, Zhao F, Yin L et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci 2011; 102: 557-564
14. Pant A, Lee II, Lu Z, Rueda BR, Schink J, Kim JJ. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One 2012; 7: e41593
15. Clarke CL, Graham JD. Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One 2012; 7: e35859
16. Mohammed H, D'Santos C, Serandour AA, Ali HR, Brown GD, Atkins et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep 2013; 3: 342-349
17. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410
18. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 2008; 68: 5619-5627
19. Rubel CA, Lanz RB, Kommagani R, Franco HL, Lydon JP, DeMayo FJ. Research resource: genome-wide profiling of progesterone receptor binding in the mouse uterus. Mol Endocrinol 2012; 26: 1428-1442
20. Takano M, Lu Z, Goto T, Fusi L, Higham J, Francis J et al. Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. Mol Endocrinol 2007; 21: 2334-2349
21. Vasquez YM, Mazur EC, Li X, Kommagani R, Jiang L, Chen R et al. FOXO1 is required for binding of PR on IRF4, novel transcriptional regulator of endometrial stromal decidualization. Mol Endocrinol 2015; 29: 421-433
22. Goto T, Takano M, Albergaria A, Briese J, Pomeranz KM, Cloke B et al. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 2008; 27: 9-19
23. Aitken A. 14-3-3 proteins: A historic overview. Semin Cancer Biol 2006; 16: 162-172
24. Quayle SN, Sadar MD. 14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens. Cancer Lett 2007; 254: 137-145
25. Titus MA, Tan JA, Gregory CW, Ford OH, Subramanian RR, Fu H et al. 14-3-3{eta} amplifies androgen receptor actions in prostate cancer. Clin Cancer Res 2009; 15: 7571-7581
26. Wakui H, Wright AP, Gustafsson J, Zilliacus J. Interaction of the ligand-activated glucocorticoid receptor with the 14-3-3 eta protein. J Biol Chem 1997; 272: 8153-8156
27. Zilliacus J, Holter E, Wakui H, Tazawa H, Treuter E, Gustafsson JA. Regulation of glucocorticoid receptor activity by 14-3-3-dependent intracellular relocalization of the corepressor RIP140. Mol Endocrinol 2001; 15: 501-511
28. De Vries-van Leeuwen IJ, da Costa Pereira D, Flach KD, Piersma SR, Haase C, Bier D et al. Interaction of 14-3-3 proteins with the estrogen receptor alpha F domain provides a drug target interface. Proc Natl Acad Sci USA 2013; 110: 8894-8899
29. Lodygin D, Diebold J, Hermeking H. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression. Oncogene 2004; 23: 9034-9041
30. Nakayama H, Sano T, Motegi A, Oyama T, Nakajima T. Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int 2005; 55: 707-715
31. Mhawech P, Benz A, Cerato C, Greloz V, Assaly M, Desmond JC et al. Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 2005; 18: 340-348
32. Winter S, Simboeck E, Fischle W, Zupkovitz G, Dohnal I, Mechtler K et al. 14-3-3 proteins recognize a histone code at histone H3 and are required for transcriptional activation. EMBO J 2008; 27: 88-99
33. Razandi M, Pedram A, Levin ER. Estrogen signals to the preservation of endothelial cell form and function. J Biol Chem 2000; 275: 38540-38546
34. Gibson DA, Greaves E, Critchley HO, Saunders PT. Estrogen-dependent regulation of human uterine natural killer cells promotes vascular remodelling via secretion of CCL2. Hum Reprod 2015; 30: 1290-1301
35. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996; 81: 3112-3118
36. Hsu SP, Ho PY, Juan SH, Liang YC, Lee WS. Progesterone inhibits human endothelial cell proliferation through a p53-dependent pathway. Cell Mol Life Sci 2008; 65: 3839-3850
37. Lebovic DI, Shifren JL, Ryan IP, Mueller MD, Korn AP, Darney PD et al. Ovarian steroid and cytokine modulation of human endometrial angiogenesis. Hum Reprod 2000; 15: 67-77
38. Okada H, Okamoto R, Tsuzuki T, Tsuji S, Yasuda K, Kanzaki H. Progestins inhibit estradiol-induced vascular endothelial growth factor and stromal cell-derived factor 1 in human endometrial stromal cells. Fertil Steril 2011; 96: 786-791
39. Goddard LM, Murphy TJ, Org T, Enciso JM, Hashimoto-Partyka MK, Warren CM et al. Progesterone receptor in the vascular endothelium triggers physiological uterine permeability preimplantation. Cell 2014; 156: 549-562
40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408
41. Sefton EC, Qiang W, Serna V, Kurita T, Wei JJ, Chakravarti D et al. MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth. Endocrinology 2013; 154: 4046-4057.